Skip to main content
Circio Holding ASA logo

Circio Holding ASA — Investor Relations & Filings

Ticker · CRNA ISIN · NO0013033795 LEI · 5967007LIEEXZXFYNS31 OL Professional, scientific and technical activities
Open in API
Filings indexed 179 across all filing types
Latest filing 2026-06-03 Regulatory Filings
Country NO Norway
Listing OL CRNA

About Circio Holding ASA

https://www.targovax.com/en/

Circio Holding ASA is a clinical-stage company developing novel medicines based on circular RNA (circRNA) and immunotherapy. The company's core focus is its proprietary circVec platform, a circular RNA expression system designed to enhance the efficacy and durability of gene and cell therapies. Circio's development pipeline is directed towards immuno-oncology, targeting difficult-to-treat solid tumors, and the application of its circRNA technology to address genetic diseases.

Recent filings

Filing Released Lang Actions
Circio Holding ASA: Last day of trading in warrants
Regulatory Filings
2026-06-03 Norwegian
Circio Holding ASA Exercise of Warrants by primary insiders - Attachment: Notification Of Trade By Primary Insiders Exercised Warrants.pdf
Director's Dealing Classification · 90% confidence The document is a notification by primary insiders (COO and CSO) of their personal transactions (exercise of warrants into shares) in Circio Holding ASA. This is an insider dealing report. It is not a share buyback by the company (which would be POS), but a director’s personal transaction. Therefore, the correct category is Director’s Dealing (DIRS).
2026-06-02 English
Circio Holding ASA Exercise of Warrants by primary insiders
Director's Dealing Classification · 98% confidence The document is a stock exchange announcement detailing warrant exercises by primary insiders (executives) of the company, including quantities, dates, and resulting holdings. This clearly describes insider share transactions by directors/executives. According to the filing definitions, this matches “Director's Dealing (DIRS): Report of personal share transactions by company directors and executives.”
2026-06-02 English
Circio and GenAssist jointly announce gene therapy research collaboration for muscle diseases and in vivo cell therapy
Regulatory Filings Classification · 25% confidence The document is a joint corporate press release announcing a research collaboration between Circio and GenAssist. It contains no financial statements, voting results, regulatory certifications, or detailed report attachments. It does not fit into categories for financial reports, board changes, capital updates, or other specialized filings. Consequently, it falls under the fallback category for general regulatory and corporate announcements (RNS).
2026-06-01 English
Circio Holding ASA Exercise of Warrants by primary insiders - Attachment: Notification Of Trade By Primary Insiders Exercised Warrants.pdf
Director's Dealing Classification · 95% confidence The document is a notification of transactions by primary insiders and their close associates, detailing insider trades (exercise of warrants, volumes, prices, dates, places) for company directors and their associates. This clearly corresponds to the Director’s Dealing category.
2026-05-29 English
Circio Holding ASA Exercise of Warrants by primary insiders
Director's Dealing Classification · 92% confidence The document details the exercise of warrants by primary insiders (board member and CEO), reporting their personal share transactions. This falls under insider trading disclosures by company directors/executives. Therefore, it is a Director’s Dealing filing.
2026-05-29 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.